CAJ | 학술논문

目的探讨加贝酯、奥曲肽和奥美拉唑联合应用在预防内镜下逆行胰胆管造影术(ERCP)术后胰腺炎(PEP)中的作用.方法将235例ERCP术后患者随机分为治疗组(125例)和对照组(110例).治疗组ERCP术后应用加贝酯1 mg/(kg·h)持续静脉滴注12 h;奥曲肽0.1 mg皮下注射,每12小时1次,12 h内应用;奥美拉唑40 mg静脉滴注,每12小时1次,24 h内应用.对照组ERCP术后静脉滴注生理盐水500 ml.ERCP术前、术后3、12、24 h检测血清淀粉酶并观察PEP的发生率.结果治疗组和对照组ERCP术后PEP的发生率分别3.20%和11.82%(P<0.01),高淀粉酶血症的发生率分别为18.40%和39.09%(P<0.05).结论加贝酯、奥曲肽和奥美拉唑联合应用可减少PEP和高淀粉酶血症的发生率.
목적 탐토가패지、오곡태화오미랍서연합응용재예방내경하역행이담관조영술(ERCP)술후이선염(PEP)중적작용.방법 장235례ERCP술후환자수궤분위치료조(125례)화대조조(110례).치료조ERCP술후응용가패지1 mg/(kg·h)지속정맥적주12 h;오곡태0.1 mg피하주사,매12소시1차,12 h내응용;오미랍서40 mg정맥적주,매12소시1차,24 h내응용.대조조ERCP술후정맥적주생리염수500 ml.ERCP술전、술후3、12、24 h검측혈청정분매병관찰PEP적발생솔.결과 치료조화대조조ERCP술후PEP적발생솔분별3.20%화11.82%(P<0.01),고정분매혈증적발생솔분별위18.40%화39.09%(P<0.05).결론 가패지、오곡태화오미랍서연합응용가감소PEP화고정분매혈증적발생솔.
Objective To investigate the prophylactic effect of gabexate mesilate, octreotide and omeprazole on post - ERCP pancreatitis. Methods Two hundred and thirty - five post ERCP patients were randomized into therapeutic group (125 cases) and control group (110 cases). After the operation of ERCP, patients in the therdpeutic group were treated with gabexate mesilate 1 mg/(kg·h) by contin-ous intravenous infusion for 12 hours, Octreotide 0. 1 mg by subcutaneous injection per 12 hours for 12 hours, Omeprazole 40 mg by intravenous infusion per 12 hours for 24 hours. The patients in the control group were applied with intravenous infusion of nermal saline 500 ml. The levels of serum amylase were detected and the incidence of PEP were observed at pre - ERCP and 5 h, 12 h ,24 h post - ERCP, respectively. Results The incidences of post - ERCP pancreatitis in the therapeatic group and control group were 3. 2% and 11. 82% , respectively ( P < 0. 01 ) , and the percentages of hyperamylasemia were 18.4% and 39.09% Respectively ( P <0. 05). Conclusions The combined use of gabexate, meilate, octreotide and omeprazole can reduce the incidences of PEP and hyperamylasemia.